Kate L Burbury

8PUBLICATIONS
54CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsGene and molecular therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 18, 2026
Usability and Acceptance Testing of an Electronic Patient-Reported Outcome Symptom Monitoring System for People Receiving Immune Checkpoint Inhibitors: Mixed Methods Study.

Julia Lai-Kwon, Claudia Rutherford, Stephanie Best

|Jan 02, 2026
Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.

Chloe A L Thompson-Peach, Daniel Thomas, Mara Dottore

|Dec 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Sasanka M Handunnetti, Amit Khot, Piers Blombery

|Feb 19, 2025
Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer (SAMSON): Pilot Randomized Controlled Trial.

Thu Ha Dang, Nilmini Wickramasinghe, Prem Prakash Jayaraman

|Oct 15, 2024
Associations between non-anaemic iron deficiency and outcomes following elective surgery for colorectal cancer: a prospective cohort study.

Lachlan F Miles, Sarah Luu, Ian Ong

|Apr 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.

Sasanka M Handunnetti, Mary Ann Anderson, Kate Burbury

Pageof 2

Frequent Collaborators

3 joint publications

Thu Ha Dang

3 joint publications

Abdur Rahim Mohammad Forkan

3 joint publications

Nilmini Wickramasinghe

3 joint publications

Prem Prakash Jayaraman